Similarly, luteolin prevented hypoxia-induced EMT of human non-small cell lung carcinoma cells (NSCLC; A549 and NCI-H1975 cell lines), as evidenced by a downregulation of mesenchymal specific markers, such as vimentin and N-cadherin; contextually, luteolin treatment repressed cancer cell motility and adhesion, interfering with integrin β1 expression and with the FAK-signaling pathway [42]. This evidence concerns the gene CDH2 and non-small cell lung carcinoma.